Market Cap 7.01M
Revenue (ttm) 300,000.00
Net Income (ttm) -8.22M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -2,740.00%
Debt to Equity Ratio 0.00
Volume 31,300
Avg Vol 484,418
Day's Range N/A - N/A
Shares Out 20.58M
Stochastic %K 9%
Beta 3.56
Analysts Strong Sell
Price Target $2.00

Company Profile

Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health epidemic in the United States and China. The company offers Generation 1, an easy-to-administer medical device which utilizes bioelectronic medical technology to treat anxiety, insomnia, and depression without the need for drugs or psychotherapy; and Generation 2 and Generation 3 headset devices for the treatment of depression, substance use disorder, traumatic br...

Industry: Medical Devices
Sector: Healthcare
Phone: 832 260 0222
Address:
1776 Yorktown, Suite 550, Houston, United States
MaskMaker
MaskMaker May. 15 at 9:23 PM
$MRNO I did sell at .75 and will wait to load again at .35. Focused on $NXL
1 · Reply
MaskMaker
MaskMaker May. 15 at 7:24 PM
0 · Reply
PAULSTOCK57
PAULSTOCK57 May. 15 at 9:51 AM
$NXL Mark White announced a modified wellness version of Gen 3 HALO that doesn’t require FDA clearance, likely to start generating revenue as quickly as possible. It’s clearly an attempt to reassure the market, but they seem to be moving away from their original DNA. Not a great signal, in my opinion. Still, I hope it works and helps fund the FDA pathway long term.
0 · Reply
MaskMaker
MaskMaker May. 15 at 2:06 AM
$AMFN All in $NXL
0 · Reply
MaskMaker
MaskMaker May. 14 at 5:23 AM
0 · Reply
MaskMaker
MaskMaker May. 12 at 5:12 PM
0 · Reply
MaskMaker
MaskMaker May. 11 at 9:32 PM
0 · Reply
MaskMaker
MaskMaker May. 11 at 1:00 AM
0 · Reply
MaskMaker
MaskMaker May. 11 at 12:59 AM
0 · Reply
MaskMaker
MaskMaker May. 9 at 9:52 PM
0 · Reply
Latest News on NXL
Nexalin Technology advances FDA Alzheimer’s strategy

2026-04-15T14:21:51.000Z - 4 weeks ago

Nexalin Technology advances FDA Alzheimer’s strategy


Nexalin announces results for 15 mA neurostimulation device

2025-11-18T14:42:34.000Z - 6 months ago

Nexalin announces results for 15 mA neurostimulation device


Why Is Nexalin Technology Stock (NXL) Down 20% Today?

2025-10-09T12:58:39.000Z - 7 months ago

Why Is Nexalin Technology Stock (NXL) Down 20% Today?


MaskMaker
MaskMaker May. 15 at 9:23 PM
$MRNO I did sell at .75 and will wait to load again at .35. Focused on $NXL
1 · Reply
MaskMaker
MaskMaker May. 15 at 7:24 PM
0 · Reply
PAULSTOCK57
PAULSTOCK57 May. 15 at 9:51 AM
$NXL Mark White announced a modified wellness version of Gen 3 HALO that doesn’t require FDA clearance, likely to start generating revenue as quickly as possible. It’s clearly an attempt to reassure the market, but they seem to be moving away from their original DNA. Not a great signal, in my opinion. Still, I hope it works and helps fund the FDA pathway long term.
0 · Reply
MaskMaker
MaskMaker May. 15 at 2:06 AM
$AMFN All in $NXL
0 · Reply
MaskMaker
MaskMaker May. 14 at 5:23 AM
0 · Reply
MaskMaker
MaskMaker May. 12 at 5:12 PM
0 · Reply
MaskMaker
MaskMaker May. 11 at 9:32 PM
0 · Reply
MaskMaker
MaskMaker May. 11 at 1:00 AM
0 · Reply
MaskMaker
MaskMaker May. 11 at 12:59 AM
0 · Reply
MaskMaker
MaskMaker May. 9 at 9:52 PM
0 · Reply
MaskMaker
MaskMaker May. 9 at 9:51 PM
0 · Reply
MaskMaker
MaskMaker May. 9 at 4:34 AM
0 · Reply
BadyBady
BadyBady May. 8 at 7:38 PM
$NXL Current report (Q1 2026): * Net loss per share = $(0.11) Previous report (Q4 2025): * Net loss per share ≈ $(0.13) Difference: * Improvement of $0.02 (i.e., the loss per share decreased).
1 · Reply
BadyBady
BadyBady May. 8 at 7:37 PM
$NXL * Significant improvement in liquidity: cash increased from $655,000 to $1.21 million.
0 · Reply
BadyBady
BadyBady May. 8 at 7:35 PM
$NXL * Tangible and structured progress toward De Novo classification with the FDA (an important regulatory pathway for novel devices such as HALO Clarity). * Execution of a formal agreement with Lindus Health (a professional CRO) to conduct a pivotal clinical trial for insomnia treatment — a major and concrete step. * The study is well-designed: 160 participants, triple-blind, sham-controlled (gold standard). * Expected start of patient recruitment in Q2 2026 (i.e., very soon). * Ongoing progress with the FDA on the Gen-2 program for Alzheimer’s treatment (Q-Submission + meeting).
0 · Reply
BadyBady
BadyBady May. 8 at 1:01 PM
$NXL 😎
0 · Reply
Stock_trading_paint
Stock_trading_paint May. 8 at 12:36 PM
$NXL its donor die time for nxl. they have about 2 months. in the past they have allways came through
1 · Reply
MaskMaker
MaskMaker May. 7 at 9:49 PM
0 · Reply
PAULSTOCK57
PAULSTOCK57 May. 7 at 6:39 PM
$NXL I wonder every day why I invested in this shitty stock 😢
0 · Reply
MaskMaker
MaskMaker May. 6 at 8:45 PM
0 · Reply
MaskMaker
MaskMaker May. 6 at 6:24 AM
0 · Reply
MaskMaker
MaskMaker May. 5 at 6:38 PM
0 · Reply